NEW YORK (GenomeWeb) – The Scottish molecular diagnostics firm DestiNA Genomics has received €1.2 million ($1.5 million) in equity investments that it will use to commercialize novel tests for cancer and infectious diseases, the economic development agency Scottish Enterprise said this week.

The new funding for the Edinburgh-based company was led by Vitro Group of Spain, the Scottish Investment Bank (part of Scottish Enterprise), Old College Capital, and private investors in the UK, Spain, Belgium, and Saudi Arabia.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.